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dietetic treatment based on avoidance of fasting.
Methods:We describe the case histories of three members of the same family with MPV17 mutations.
Results:Two patients had a very severe and progressive liver disease: 1 died in the ﬁrst year of life and the other under-
went liver transplantation. The third patient, now 13 years of age, had a milder form of liver disease and developed pro-
gressive ataxia. Psychomotor involvement at onset of disease was mild or absent. No patient had severe hyperlactataemia.
In vivo functional studies on two patients showed no hyperlactataemia even after intravenous and oral glucose loading,
regular fasting hypoglycemia 3–4 h after meals and no response to glucagon. Liver function tests improved when patients
received continuous iv glucose infusion or were regularly fed every 3 h.
Conclusions:These clinical and biochemical features allow us to diﬀerentiate patients withMPV17 mutations from other
liver MDS and suggest that regular glucose intake at short intervals may be beneﬁcial in slowing the progression of the
disease.
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MPV17 is a recently identiﬁed nuclear gene whose
mutations cause an autosomal recessive hepatocerebral
mitochondrial DNA depletion syndrome (MDS) [1].
This disease is identical to another disorder called
Navajo neurohepatopathy (NNH, OMIM #256810)
[2–4], a relatively frequent disease among Navajo peo-
ple, with a prevalence of 1:1600 live births. The three dif-
ferent phenotypes which have been described in NNH,
are in fact a ‘‘continuum” from the infantile form, show-
ing severe liver disease in the ﬁrst months of life and
death before 2 years of age, to the classic form domi-
nated by progressive neurological signs, milder liver dis-
ease and survival into adulthood [4].
A single mutation of MPV17, inherited from a com-
mon ancestor, is responsible for NNH. Only a few non-
Navajo patients have been identiﬁed so far [1,5–7], most
of whom have shown the severe phenotype dominated
by liver disease in infancy. No treatment is available
for this disease, besides palliative care. The only thera-
peutic option in selected cases, was liver transplantation
when the patient showed isolated liver disease with no
other organ involvement [2,4,8]. In this paper, we report
the clinical and histological ﬁndings of three of the ﬁve
patients initially studied by Spinazzola et al. [1] and1 a  -pedigree family 1
Lactate (mMol/L)
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Fig. 1. (a) Family pedigree: patient 1 (VII-2), 2 (VII-3) andthe results of dietetic treatment aimed at stopping liver
disease progression in two of them. The clinical features
of the two other patients have already been reported
elsewhere [9,10].
2. Patients and methods
2.1. Case reports
2.1.1. Patient 1
Born at full term from healthy ﬁrst cousin parents belonging to a
highly inbred family (Fig. 1a), this baby boy was mildly jaundiced in
the ﬁrst month of life while he was breast fed on demand. At 1 month,
blood tests showed mild mixed hyperbilirubinemia (total 2.6, conju-
gated 1.2 mg/dL), liver cells necrosis (ALT 119, AST 153 U/L), chole-
stasis (gamma-GT 320 U/L) and neutropenia (neutrophils 603 mm3),
which were conﬁrmed at 3.5 months when he was hospitalized. On that
occasion, severe hypoglycemia was observed after 7 h of fasting (glu-
cose 0.38 mmol/L), which resolved with iv glucose administration; lac-
tate was mildly elevated (3.2 mmol/L). An improvement in blood test
results was observed after a few days of continuous i.v. glucose infu-
sion and later, with regular bottle feeds every 3 h. At 5.5 months, after
2 months of a strict diet consisting of 8 feeds per day, growth was at
the 50th percentile for weight and length. Hepatomegaly was still pres-
ent but the infant had no jaundice (total bilirubin 0.8 mg/dL), im-
proved liver function (ALT 47, AST 93, gamma-GT 148), normal
neutrophils (4750 mm3), normal psychic development and only mild
axial hypotonia. Two brief fasting tests with glucose/lactate proﬁle,
showed a fasting tolerance of 3.5 h (glucose 2.4 and 2.1 mM) without
hyperlactatemia (Fig. 1b). Glucagon test at 2.5 h fasting (baseline glu-







































3 (VI-4). (b–d) Results of functional tests in patient 1.
R. Parini et al. / Journal of Hepatology 50 (2009) 215–221 21745 min when the test was stopped (Fig. 1c). A glucose challenge (2.5 g/
kg) showed normal lactate and normal absorption of glucose which de-
creased progressively from 7.5 at 300 to 1.9 mM at 1800 (Fig. 1d). The
patient was re-admitted to hospital 3 weeks later with hypotonia, jaun-
dice, ascites and melena after having had severe gastroenteritis for 6
days. Blood tests showed an abrupt worsening of liver function (total
bilirubin 16.7, conjugated 9 mg/mL, ALT 185, AST 489 U/L, gamma-
GT 330 U/L). Despite intensive treatment, the infant soon deteriorated
and died at the age of 7 months.
2.1.2. Patient 2
Patient one’s younger brother, was born at term after an uneventful
pregnancy. On the basis of the beneﬁcial eﬀects of the diet seen in patient
1, patient two was breast fed regularly every 3 h from birth. In the third
week of life a mild increase of ALT, AST and gamma-GT was ﬁrst
observed (51, 108, 78 U/L, respectively). Pre-feeding glucose and lactate
were normal, aswas cerebrospinal ﬂuid (CSF) lactate (1659 lmol/L, n.v.
800–2100). A weekly follow-up was started and his parents were
instructed to bring him to the hospital immediately, whenever he devel-
oped common childhood diseases and/or did not have regular food
intake. Between 1 and 25 months of age, 65 blood samples were taken
and he was hospitalized four times for common childhood complaints.
On each occasion, when admitted with initial symptoms like mild anor-
exia or vomiting, he always had hypoglycemia (range 0.8–2.5 mmol/L),
associated with biochemical signs of increased hepatocellular necrosis
and cholestasis (range: ALT 150–198, AST 222–288, gamma-GT 200–
350). At discharge, after 4–6 days of continuous i.v. glucose infusion,
liver function tests had normalized (range: ALT 35–43, AST 50–58,
gamma-GT 50–64). In those periods when he was free of infections
and could be regularly fed at home, hepatocellular damage indexes
increased only moderately (range: ALT 50–180, AST 35–150). Fasting
tolerance was 4 h at 1 month (glucose 2.5 mmol/L) and still 4 h at 15
months (glucose 3.0 mmol/L), while treated with 5 g of raw corn-starch
after eachmeal. He reached ﬁrst year developmental milestones at a nor-
mal age and was able to walk unaided at 12 months. Weight and height
were constantly at the 50th percentile. Nerve conduction studies, devel-
opmental quotient (DQ) and cerebral magnetic resonance imaging
(MRI)were normal at 24months. At 25months, after a diﬃcult decision
taken together with the family, he underwent liver transplantation. We
considered that he was at reasonable risk of sudden liver function dete-
rioration like his brother, if he were to be aﬀected by a more severe com-
mon illness than those he had had to date. Immediately after
transplantation, he was shifted to a free diet with normal night fasting
and no hypoglycemia was detected. At 30months he beganwalkingwith
an unsteady gait and was unable to climb stairs. A clinical diagnosis of
ataxiawasmade andnerve conduction studies showed severemotor-sen-
sory axonal polyneuropathy. Cerebral MRI and electroencephalogram
(EEG) were normal. At 52months DQwas 96 withWPPSI scale (verbal
97, performance 96).
2.1.3. Patient 3
This female patient is a relative of the ﬁrst 2 patients (Fig. 1a). She
had her ﬁrst symptomatic hypoglycemia at 5 months with glucose
2.4 mM; ALT and AST were 165 and 237 U/L, respectively. Another
three hypoglycemic crises occurred between then and 3 years of age.
Repeated blood tests between 3 and 10 years of age showed normal
transaminases and increased gamma-GT (range 96–163 U/L). Liver
ultrasound showed ﬁbrosis and steatosis with areas of cirrhosis. A fast-
ing test performed at 6 years was stopped at 16 h for hypoglycemia
(1.3 mmol/L) with increased plasma lactate (4.5 mmol/L). The gluca-
gon test showed a normal increase of glucose after 6 h of fasting. From
3 to 10 years of age, she developed failure to thrive (3rd percentile for
weight and height), right thoracic scoliosis, muscle hypotrophy of the
lower limbs, ataxia and progressively worsening brain lesions in the
cerebellar white matter and in the Substantia Nigra at MRI. Cognitive
function was normal until 7 years and then worsened: Intelligence
Quotient (IQ) (WISC-R) was 64 (verbal 75, performance 55) at 10
years. Slit-lamp examination showed a small corneal scarring in the left
eye. Corneal sensitivity, fundus oculi and electroretinogram (ERG)
were normal. Visual and somatosensory evoked potentials demon-
strated abnormalities in the central transmission of the stimuli. Nerve
conduction studies showed severe demyelinating damage to both mo-
tor and sensory peripheral nerves.2.2. Methods
Tissue samples: liver, muscle and skin biopsies were performed after
informed parental consent. Tissues for biochemical assays were immedi-
ately frozen and stored at80 C until assayed. Skin biopsies and ﬁbro-
blasts cultures were performed according to usual routine procedures.3. Biochemical analysis and molecular studies
Speciﬁc activities of individual respiratory chain com-
plexes were measured on tissue homogenates by spectro-
photometric assay. Speciﬁc activities of each complex
were normalized to that of citrate synthetase (CS), a
mitochondrial matrix enzyme indicator of mitochon-
drial mass [11]. Nucleotide sequence analysis was carried
out as described by Spinazzola et al. [1].4. Morphological analyses
All liver sampleswere routinely formalin ﬁxed and par-
aﬃn embedded. Sections were stained with hematoxylin–
eosin (H&E), Masson trichrome for collagen tissue, PAS
and PAS-diastase for glycogen, Pearl’s for iron and
Orcein for copper. Patients 1 and 2 both had two histolog-
ical examinations over time. They were compared by
means of a score from 0 to 4 attributed to 12 diﬀerent his-
tologic features (hepatocellular necrosis, ballooning, cho-
lestasis, canalicular cholestasis, bile duct proliferation,
macrovescicular and microvescicular steatosis, portal
and lobular inﬂammation, ﬁbrosis, Kupﬀer cells activa-
tion, glycogen content). Morphological analysis of skele-
tal muscle was carried out as previously described [12].5. Statistical analysis
Analysis of ALT and AST was carried out every two
weeks in patient 2 and the results were divided into three
diﬀerent sets of data according to the clinical conditions of
the child: 1.well being (45 values); 2. admission to hospital
for common childhood diseases (eight values); 3. dis-
charge from hospital after at least 3 days of continuous
iv glucose infusion (four values). The numbers of data
were diﬀerent in the three diﬀerent settings and were ana-
lysed by theKruskal–Wallis one-way analyses of variance
by ranks.6. Results
6.1. Biochemical investigations and molecular analysis
Liver respiratory chain activities and molecular analy-
sis of the three patients are summarized in Table 1. Low
activities of Complex I (CI), Complex III (CIII) andCom-
Table 1
Summary of biochemical, molecular and clinical ﬁndings of the three patients.
Patient Liver tissue activities Liver MtDNA depletion % Genotype Outcome
CI CII CIII CIV
1 0.1 37 22 17.6 3 ± 5 p.R50Q/p.R50Q D 7 months
2 7.6 67 55 38 11 ± 2 p.R50Q/p.R50Q A 6 years, liver tx, ataxia
3 9.1 72 50 56 22 ± 8 p.R50Q/p.R50Q A 13 years ataxia
Controls 19.0 ± 9.3 54 ± 17 83 ± 22 70 ± 17 100%
Activities are expressed as nmoles of substrate/min/mg of protein and normalized to citrate synthetase. CI, CII, CIII and CIV indicate ‘‘complex I,
complex II, complex III and complex IV”.
D indicates ‘‘died”, A ‘‘alive” and tx ‘‘transplantation”.
MtDNA depletion is expressed as percentage of normal controls.
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in liver homogenates, while they were normal in muscle
homogenates and ﬁbroblast cultures (not shown).7. Morphological investigations
Liver samples were analyzed in patients 1 and 2
(Fig. 2). Liver biopsy from patient 1 taken 3 days before
death, showed submassive hepatic necrosis (Fig. 2A and
B; score 24) withmicro andmacrovescicular steatosis, dif-
fuse hepatocyte ballooningwith focal giant cell formation
and occasional canalicular bile plugs; liver cells necrosis
was repaired by ﬁbrosis and bile ductular proliferation,
with accompanying cholangiolitis but without the forma-
tionof typical cirrhotic nodules. PAS staining showedgly-
cogen depletion.Histology of the liver taken at autopsy, 3
days later, revealed a much more severe necrosis, with
marked ballooning of residual hepatocytes, cholestasis
and diﬀuse ductular proliferation (Fig. 2C and D; score
28). In patient 2, the ﬁrst biopsy, taken at 3 weeks of
age, demonstrated a normal liver structurewith the excep-
tion of focal swelling of perivenular centrolobular hepato-
cytes, accompanied byminimal focal perivenular ﬁbrosis,
inﬂammation and mild Kupﬀer cell activation, with pres-
ence of ceroid pigment deposits. Cytoplasmic glycogen
was normal with PAS staining (Fig. 2E; score 7). Explant-
ed liver (2 years of age) showed structural alterations
mostly limited to the centrolobular areas: microvescicular
steatosis and few ballooned hepatocytes, with mild Kupf-
fer cell activation; portal spaces showed mild irregular
ﬁbrous expansion,with thin and largely incomplete portal
to portal septa, characterized by mild bile ductular prolif-
eration (Fig. 2F–H; score 14).
Histopathology and electron microscopy of the mus-
cle, performed on patient 3 was normal and no ragged
red ﬁbers were observed.8. Statistical analysis
Patient 2’s transaminases values were statistically ana-
lyzed in three diﬀerent settings: well being, admissions,discharges. A signiﬁcant diﬀerence was found between
the three sets of data (ALT: KW2 = 16.71014,
p = 0.0002; AST: KW2 = 26.67904, p = 0.000). Multiple
comparisons showed signiﬁcant diﬀerences both for
ALT andAST. In particular, for ALT, between set 1 (well
being) and set 2 (admissions) (p = 0.006597) and between
set 2 (admissions) and set 3 (discharges) (p = 0.000268);
for AST, between set 1 and 2 (p = 0.000107), set 2 and 3
(p = 0.000004) and set 1 and 3 (p = 0.028232) (Kruskal–
Wallis one-way analyses of variance by ranks).9. Discussion
An apparently isolated liver disease was detected in
two of our three patients, very early in life. As already
pointed out by Wong et al. [5], unlike other MDS [13–
17], neurological involvement in this disease is very mild
at onset, being limited to generalized hypotonia with
preserved cognitive development. Due to this presenta-
tion, dominated by liver disease, many other metabolic
disorders were ruled out before searching for a mito-
chondrial disorder.
A total of 34 patients [1–3,5–7] have already been
described with proven MPV17 mutation and/or NNH.
Of these, 24 had severe liver failure in infancy or child-
hood, while 10 patients, nine of whom are Navajos, have
the so called classical form with peripheral neuropathy
and less liver involvement. Liver transplantation was
performed in the ﬁrst 2 years of life in four patients with
the severe form [1–3] but also in an 11 year old patient
with the classical prevalently neuropathic presentation
who had developed liver carcinoma [2,3]. Other patients
with the attenuated form died of liver cirrhosis in their
second decade of life [2–4]. All the patients with the
attenuated form are homozygous for the p.R50Q muta-
tion (the Navajo patients and one of ours), suggesting a
reduced severity of this mutation compared to the oth-
ers. However, the common ﬁnding of intrafamilial vari-
ability of phenotype may also suggest extragenic
inﬂuences on phenotype.
Liver histological features of our patients are similar
to those reported in NNH [2,3] and other patients with
Fig. 2. Patient 1: Biopsy taken 3 days before the death demonstrating large areas of conﬂuent necrosis (A, H&E 40) replaced by ﬁbrosis and ductular
proliferation, with diﬀuse ballooning of speared hepatocytes (B, H&E 400). Liver from autopsy showed complete lobular derangement due to massive
necrosis (C, Masson trichrome 40), replaced by bile duct proliferation and canalicular cholestasis of residual hepatocytes (D, H&E 400). Patient 2:
Biopsy taken at 3 weeks demonstrating a structurally normal liver, with light cytoplasmic swelling of perivenular hepatocytes (E, Masson 40). The
explanted liver showed moderate structural alteration, with preserved centrolobular veins and portal to portal ﬁbrous septa (F, Masson 40). Higher
magniﬁcations demonstrate moderate septal proliferation of bile ducts (G, H&E 400) and lobular micro vescicular steatosis (H, H&E 400).
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reported for other MDS [17]. We had the opportunity
to study liver specimens of patients 1 and 2, at diﬀerent
ages. The histological ﬁndings of patient 2 at 3 weeks
and at 25 months of age and those of his older brother
at 8 months of age, 3 days before death, well illustrates
the progression of liver disease in MPV17 patients.
Accordingly, we could say that the ﬁrst histological
signs of this liver disease consist of focal vacuolization
in perivenular centrolobular hepatocytes, accompanied
by Kupﬀer cell activation. Liver cell necrosis in this dis-
ease is ﬂuctuating, also depending on concomitant dis-
eases. Evolution to prevalent ﬁbrosis and/or cirrhosisis likely dependent on the entity of recurrent episodes
of hepatocellular damage.
We would like to highlight some particular biochem-
ical ﬁndings in our patients that are diﬀerent from other
MDS. First, lactic acidosis was not a major ﬁnding, as
also described by Navarro-Sastre et al. [7], with maxi-
mum values of 4–6 mmol/L only when the patients were
already very compromised. Second, hypoglycemia in the
two patients who were thoroughly investigated, consis-
tently ensued 3–4 h after the meal, while in other liver
MDS, hypoglycemia usually develops after a more pro-
longed fasting (personal observation). Furthermore,
oral glucose challenge or continuous iv glucose adminis-
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otherwise commonly seen in other respiratory chain dis-
orders [18]. These physiological features are similar to
those of glycogen storage disease type I where both gly-
cogenolysis and gluconeogenesis are impaired and
energy production is only based on glycolysis. Unfortu-
nately an enzymatic assessment in liver tissue for glyco-
genolysis or gluconeogenic pathway was not done in our
patients. Since patient 1 improved both clinically and
biochemically when strictly fed every 3 h, we started
feeding his younger brother every 3 h from birth. Like
his sibling, this patient had signs of hepatocellular
necrosis and cholestasis very early in life. His fasting tol-
erance lasted for a maximum of 4 h and his liver func-
tion tests severely worsened whenever he had an even
mild deviation from his usual caloric intake. Taken
together, these observations strongly suggest that glu-
cose and regular caloric intake have a role in protecting
liver from hepatocyte necrosis and preserving liver
architecture in MPV17 mutant patients.
From a functional point of view, the liver disease in
patient 3 was less severe than that of her cousins. To
date, she is in fact the only non- Navajo patient who
may be classiﬁed as having the classical form. She had
biochemical signs of hepatocellular necrosis only during
the hypoglycemic episodes and, unlike her cousins, she
had better fasting tolerance and a clear response to
glucagon.
With the exception of liver transplantation which has
only been performed in a few cases [2,3,7], no other
treatment for this disease has been reported to date.
At least two patients died suddenly after an abrupt
worsening of their liver disease [2,5]. Dietetic treatment
could be helpful in similar cases as supportive care,
while waiting for liver transplantation to be performed.
No clear response to dietetic treatment has been
observed in the past for liver MDS [13,14]. We report
here that in two patients withMPV17 related MDS, diet
based feeding every 3 h was useful in slowing progres-
sion of liver damage. The glucose challenge test in
patient 1 and the blood tests during glucose infusions
in patient 2 showed that both patients were able to prop-
erly use glucose as a fuel without producing lactate, sug-
gesting that dietetic treatment may be beneﬁcial in other
MPV17 mutant cases. Physicians may be reluctant to
perform stress and challenge tests in very sick patients
or to shift them to a rigid diet without a proven beneﬁt.
However, our data suggest trying continuous glucose
infusion for a few days in any MDS patient with liver
involvement, even before having reached a speciﬁc diag-
nosis: if a reduction of transaminases is obtained, the
same patient should start strict feeding every 3 h.
Results from patient 2 and those reported among the
other transplanted patients [2,4,7] indicate that liver
transplantation did not prevent the evolution of periph-
eral and central neuropathy. Therefore, the decision topursue this procedure remains controversial, particu-
larly considering the risks of the surgical procedure
and the lifelong dependence on immunosuppressive
treatment. However, patient 2 underwent liver trans-
plantation, in consideration of the impending risk of
developing acute fatal liver failure like his older brother,
prior to knowing the natural history and the speciﬁc
genetic cause of the disease.
In conclusion, our MPV17 patients were character-
ized, as other previously reported patients [2–5], by mild
or absent neurological involvement at onset, absent or
mild hyperlactatemia, consistently severe hypoglycemia
3–4 h after meals, no hyperlactatemia after glucose load-
ing, beneﬁcial eﬀect of i.v. glucose and frequent feeding
on liver function tests. The peculiar clinical and labora-
tory features of MPV17-related MDS can help diﬀeren-
tiate it from other MDS forms. Our experience suggests
that the impairment of liver function in MPV17-related
MDS may be treated, or its progression slowed down,
by a strict diet based on frequent meals. It will be of
interest to conﬁrm this observation in a larger series of
patients. A more thorough understanding of the func-
tion of the MPV17 protein is also needed to devise bet-
ter therapeutic strategies for this disease.
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